The utilization of CRISPR in gene and cell therapy product development has become increasingly vital in modern biotechnology. Its precise targeting ability and efficient gene editing capabilities have revolutionized the field, offering unprecedented potential for therapeutic innovation. sgRNA as the key GE component in the CRISPR system, its purity is crucial for developing ideal CGT products.

Impurities exist in sgRNA can lead to off-target effects, reducing the precision and efficacy of the gene editing process. Regulatory agencies have also published guidelines indicating more stringent requirements for genome editing (GE) components, such as sgRNA quality testing.

In order to provide our clients with a more complete product quality control (QC) testing standards that meet the regulatory requirements, as well as deliver safer products, GenScript developed a full spectrum of validated QC items that can help our clients to characterize the sgRNA, including a comprehensive sgRNA purity analysis approach. Read our new case study to discover how GenScript’s sgRNA sample purity analysis approach can help fast track your GCT development.